Reference | Route | Dose | Parameters | Parameters Corrected for Dose | ||||
---|---|---|---|---|---|---|---|---|
Cmax | AUCa | T1/2 | Cmax | AUCT | ||||
ng/ml | ng/ml*h | h | (ng/ml)/mg | (ng/ml*h)/mg | ||||
MSI Study | Stage 1: | |||||||
MSI-195 | Oral | 400 | 1045.4 | 4643.9 | 16.0 | 2.6 | 11.6 | |
MSI-195 | Oral | 800 | 3255.5 | 9360.6 | 8.9 | 4.1 | 11.7 | |
MSI-195 | Oral | 1600 | 4808.8 | 16,511.0 | 7.8 | 3.0 | 10.3 | |
Stage 2: | ||||||||
MSI-195 Fast | Oral | 800 | 3280.8 | 9434.4 | 11.5 | 4.1 | 11.8 | |
MSI-195 Fed | Oral | 800 | 1461.0 | 5224.7 | 33 | 1.8 | 6.5 | |
SAMe (NM) | Oral | 1600 | 1984.3 | 6643.8 | 9.3 | 1.2 | 4.2 | |
Literature Studies | Loehrer et al. [17] | Oral | 400 | 144 | 489 | 1.7 | 0.4 | 1.2 |
Yang et al. [12] | Oral | 1000 | 974 | 4748 | 6.2 | 1.0 | 4.7 | |
Yang et al. [12] | IV | 1000 | 67,600 | 162,000 | 4.1 | 67.6 | 162.0 | |
Guilidori et al. [16] | IV | 100 | 8320 | 7833 | 1.35 | 83.2 | 78.3 | |
Guilidori et al. [16] | IV | 500 | 31,300 | 42,500 | 1.68 | 62.6 | 85.0 | |
Stramentinoli et al. [18] | IM | 35 | - | 4300 | 1.35 | - | 122.9 | |
Stramentinoli et al. [18] | IV | 35 | - | 4000 | 1.35 | - | 114.3 |